Recent results from the European Society of Cardiology meeting

Brief clinical trial results from the recent ESC meeting in Paris:

ARISTOTLE: Apixaban (factor Xa inhibitor) bests warfarin in preventing stroke in patients with non-valvular atrial fibrillation.

PRODIGY: Increased bleeding complications in patients taking 24 vs. 6 months of dual anti platelet therapy (aspirin + clopidogrel).

CORP: Colchicine prevents recurrent pericarditis.

ISAR-CABG: DES drug-eluting stents) beat BMS (bare metal stents) in SVG's at one year.

dal-VESSEL: Dalcetrapib raises HDL cholesterol but not blood pressure.

RUBY-1: No benefit of using factor Xa inhibitor in ACS

Read all about it here: http://www.escardio.org/congresses/esc-2011/congress-news/Pages/welcome.aspx

Leave a Reply

Your email address will not be published. Required fields are marked *

* Copy This Password *

* Type Or Paste Password Here *

420,358 Spam Comments Blocked so far by Spam Free Wordpress